Finnish biotech company LifeGlue Technologies has successfully raised €705,000 in seed funding, marking a significant milestone in its mission to deliver animal-free material that enables companies and research groups globally to grow human tissues in laboratory settings. The Estonian Business Angels Network (EstBAN) took the lead as the first investor in this round, which was announced during sTARTUp Day held in Tartu.
LifeGlue's innovative technology promises to transform the landscape of biomedical research and regenerative medicine. The funds are expected to catalyze further advancements in their product capabilities, potentially expanding their applications across various sectors.
